Introduction {#Sec1}
============

With the increased use of mammography, more and more women are diagnosed with various subtypes of benign breast disease (BBD) (Kuzma [@CR20]; Kalache [@CR18]). Since BBD is a very important risk factor for subsequent breast cancer, it is necessary to estimate the risk of breast cancer for specific histological categories. BBD is usually subdivided into non-proliferative disease (NP), proliferative disease without atypia (PDWA), and atypical hyperplasia (AH) (Dupont and Page [@CR9]; Gail et al. [@CR13]; Fitzgibbons et al. [@CR12]). AH is usually categorized into atypical ductal hyperplasia (ADH) and atypical lobular hyperplasia (ALH). Women with PDWA had a 1.5--2 times higher risk of breast cancer compared to women without BBD, while an approximately four-fold increased risk of breast cancer for AH was corroborated by previous studies (Dupont and Page [@CR9]; Hartmann et al. [@CR15]; Page et al. [@CR28]; Dupont et al. [@CR10]; London et al. [@CR23]). However, it is unclear whether breast cancer risk is higher in cases of ADH versus ALH (Degnim et al. [@CR7]; Kabat et al. [@CR17]; Collins et al. [@CR6]). Some studies (Collins et al. [@CR6]; Kabat et al. [@CR17]) suggested that ALH was associated with a higher risk than ADH, so that more active management should be considered for women with ALH. However, breast cancer risk was similar for ADH and ALH in a Mayo cohort study (Degnim et al. [@CR7]). Family history is also a key component of breast cancer risk assessment (Ready and Arun [@CR30]). Women with a positive family history and a special subtype of BBD may have increased risk. However, it is still unclear whether a positive family history increases breast cancer risk in women with all subtypes of BBD (Dupont and Page [@CR9]; London et al. [@CR23]; Carter et al. [@CR4]; Degnim et al. [@CR7]).

According to American Society of Clinical Oncology (ASCO) clinical practice guideline, women at risk should be considered with optimal management, including increased screening, chemoprevention, and prophylactic surgery. For women at average risk, screening mammography should be performed every 1--2 years, while for women at high risk, screening mammography should be performed every 6--12 months (Griffin and Pearlman [@CR14]). Although AH and a positive family history were associated with increased breast cancer risk, the majority of women with proliferative disease (PD) and/or a positive family history would not develop breast cancer. Thus, it is necessary to identify individuals with high breast cancer risk. The purpose of this meta-analysis was to investigate the subtype of BBD with high breast cancer risk and the influence of a positive family history on various subtypes of BBD.

Methods {#Sec2}
=======

Search strategy {#Sec3}
---------------

Meta-analysis was performed as described previously (Liu et al. [@CR22]). Relevant studies were selected by searching PubMed (updated on September 2010), using the following terms: case--control, breast cancer or breast neoplasm, and benign breast disease or proliferative disease or atypia. Two reviewers (Zhou WB and Xue DQ) independently evaluated titles and abstracts of the identified papers. References in identified articles and previous reviews were also reviewed for possible inclusion. Only those published studies in English language with full text articles were included in this meta-analysis. Studies were included if they met the following criteria: (1) the diagnosis of BBD and breast cancer was confirmed histopathologically; (2) BBD that was subdivided into NP, PDWA, and AH by biopsy; (3) a case--control study examining the association between BBD and breast cancer risk; and (4) sufficient published data for estimating an odds ratio (OR) with 95% confidence interval (CI). For overlapping studies, only the one with the largest sample numbers was selected.

Data extraction {#Sec4}
---------------

Information was carefully extracted from all the eligible studies independently by two reviewers (Zhou WB and Xue DQ). The following variables were extracted from each study if available: first author's name, publication year, country of origin, study design, numbers of cases and controls, numbers of cases and controls in different subtypes of BBD, and numbers of cases and controls in different subtypes of BBD on family history. After disagreement was resolved by discussion, all the data were reached consensus.

Statistical analysis {#Sec5}
--------------------

Crude odds ratios with 95% confidence interval were used to assess the association between the subtypes of biopsy-proved BBD and subsequent breast cancer risk. Otherwise, the association between different subtypes of BBD on family history and subsequent breast cancer risk was also evaluated. The between-study heterogeneity was tested with Q statistics (Lau et al. [@CR21]). If *P* \< 0.10, the between-study heterogeneity was considered to be significant. When between-study heterogeneity was absent, the fixed-effects model (the Mantel--Haenszel method) (Mantel and Haenszel [@CR24]) was used to calculate the pooled OR. Otherwise, a random-effects model (the DerSimonian and Laird method) (DerSimonian and Laird [@CR8]) was selected. Publication bias was investigated by funnel plot, in which the standard error of log (OR) of each study was plotted against its log (OR). Funnel plot asymmetry was assessed by the method of Egger's linear regression test, a linear regression approach to measure funnel plot asymmetry on the natural logarithm scale of the OR. The significance of the intercept was determined by the t test as suggested by Egger, and a *P* value less than 0.05 was considered significant (Egger et al. [@CR11]). All analyses were performed using the software Stata version 11.0 (Stata Corporation, College Station, TX, USA).

Results {#Sec6}
=======

Eligible studies {#Sec7}
----------------

Ten case--control studies were included in this meta-analysis. Of the ten studies, eight were nested within large cohort studies (Table [1](#Tab1){ref-type="table"}). As shown in Table [1](#Tab1){ref-type="table"}, compared to NP, nine studies (Kabat et al. [@CR17]; Stark et al. [@CR32]; Boulos et al. [@CR2]; McDivitt et al. [@CR26]; Shaaban et al. [@CR31]; Worsham et al. [@CR35]; Collins et al. [@CR6]; Byrne et al. [@CR3]; Bianchi et al. [@CR1]) were eligible for subsequent breast cancer risk of PDWA and AH, including 2340 cases and 4422 controls. Of the nine studies, subsequent breast cancer risk of ADH was reported in five studies (Stark et al. [@CR32]; Shaaban et al. [@CR31]; Collins et al. [@CR6]; Worsham et al. [@CR35]; Kabat et al. [@CR17]), and subsequent breast cancer risk of ALH was reported in four studies (Shaaban et al. [@CR31]; Collins et al. [@CR6]; Worsham et al. [@CR35]; Kabat et al. [@CR17]). As shown in Table [2](#Tab2){ref-type="table"}, four studies (Kabat et al. [@CR17]; Dupont et al. [@CR10]; McDivitt et al. [@CR26]; Collins et al. [@CR5]) were eligible for investigating the interplay between BBD (NP and PD) and a first-degree family history of breast cancer, including 1,377 cases and 2,630 controls. Of the four studies, three studies (Dupont et al. [@CR10]; McDivitt et al. [@CR26]; Collins et al. [@CR5]) reported the interplay between the subtypes of PD and a first-degree family history.Table 1Characteristics of case--control studies about histologic stratification included in the meta-analysisAuthorPopulationYearDesignCasesControlsTotalNPPDWAAH (ADH/ALH)TotalNPPDWAAH (ADH/ALH)BianchiItaly (CSPO)1992Nested case--control6245611315277317McDivittUSA (CSHS)1992Case--control417227124662481546826StarkUSA (Mayo)2000Nested case--control13798345 (5/0)156115374 (4/0)ByrneUSA (BCDDP)2001Nested case--control31862198583589422341ShaabanBritish2002Case--control117623817 (7/10)3452487918 (11/7)CollinsUSA (Nurse)2007Nested case--control3959920096 (45/36)1,610611839160 (103/42)BoulosUSA (NBC)2008Nested case--control77243914152565838WorshamUSA (HFHS)2009Nested case--control2024812529 (22/10)61423434931 (22/9)KabatCa, USA, UK2010Nested case--control61519039332 (13/16)62425036212 (6/5)*NP* non-proliferative, *PDWA* proliferative disease without atypia, *AH* atypical hyperplasia, *ADH* atypical ductal hyperplasia, *ALH* atypical lobular hyperplasiaTable 2Characteristics of case--control studies about family history included in the meta-analysisAuthorPopulationYearDesignCasesControlsNon-(FH + PD)Non-FH, PD (PDWA/AH)FH, non-PDFH + PD (PDWA/AH)Non-(FH + PD)Non-FH, PD (PDWA/AH)FH, non-PDFH + PD (PDWA/AH)McDivittUSA (CSHS)1992Case--control144108 (66/42)2025 (19/6)10661 (44/17)157 (5/2)DupontUSA (BCDDP)1993Nested case--control2045 (36/9)1515 (10/5)87102 (93/9)1919 (18/1)CollinsUSA (Nurse)2006Nested case--control75221 (151/70)2475 (49/26)505817 (693/124)106182 (146/36)KabatCa, USA, UK2010Nested case--control14734033702153002762*FH* first-degree family history, *PD* proliferative disease, *PDWA* proliferative disease without atypia, *AH* atypical hyperplasia

Meta-analysis {#Sec8}
-------------

Table [3](#Tab3){ref-type="table"} showed the main results of this meta-analysis. Relative to NP, the OR for PDWA was 1.44 (95% CI 1.28--1.63, *P* = 0.80 for heterogeneity); while two studies published in 1992 were excluded, the OR for PDWA was 1.48 (95% CI 1.30--1.69, *P* = 0.73 for heterogeneity); for AH, OR was 2.81 (95% CI 1.91--4.12, *P* \< 0.01 for heterogeneity); while two studies published in 1992 were excluded, the OR for AH was 2.72 (95% CI 1.83-4.04, *P* = 0.01 for heterogeneity); for ADH, OR was 2.93 (95% CI 2.16-3.97, *P* = 0.48 for heterogeneity) (Fig. [1](#Fig1){ref-type="fig"}); for ALH, OR was 5.14 (95% CI 3.52--7.52, *P* = 0.98 for heterogeneity) (Fig. [2](#Fig2){ref-type="fig"}).Table 3Summary ORs and 95% CI of subsequent breast cancer riskModifying factorHistologyOdds ratio95% CI*P* value for heterogeneityHistologyNP1.00ReferencePDWA1.441.28--1.630.80AH2.811.91--4.12\<0.01\*ADH2.932.16--3.970.48ALH5.143.52--7.520.98Family history AbsentNP1.00ReferencePD1.671.41--1.970.57PDWA1.391.10--1.750.48AH3.102.27--4.250.11 PresentNP1.641.21--2.220.16PD2.301.80--2.940.20PDWA2.351.66--3.330.93AH4.872.89--8.200.26*NP* non-proliferative disease, *PD* proliferative disease, *PDWA* proliferative disease without atypia, *AH* atypical hyperplasia, *ADH* atypical ductal hyperplasia, *ALH* atypical lobular hyperplasia\* Estimates for random-effects modelFig. 1Forest plot for meta-analysis of breast cancer risk from BBD for women with atypical ductal hyperplasia compared to non-proliferative disease. The width of the *horizontal line* represents the 95% CI of the individual studies, and the *square* proportional represents the weight of each study. The *diamond* represents the pooled OR and 95% CIFig. 2Forest plot for meta-analysis of breast cancer risk from BBD for women with atypical lobular hyperplasia compared to non-proliferative disease. The width of the *horizontal line* represents the 95% CI of the individual studies, and the *square* proportional represents the weight of each study. The *diamond* represents the pooled OR and 95% CI

Family history was an independent risk factor in this meta-analysis. When the women without a first-degree family history and PD were used as reference group, women with a first-degree family history and AH had a highest risk (Table [3](#Tab3){ref-type="table"}) (OR = 4.87, 95% CI 2.89--8.20, *P* = 0.26 for heterogeneity).

When the women in different histological subtypes without a first-degree family history were used as reference group, a first-degree family history did not increase risk in women with AH (OR = 1.39, 95% CI 0.82--2.37, *P* = 0.53 for heterogeneity). However, a first-degree family history increased risk in women with other histological subtypes. Relative to women without family history, for NP, the OR for women with family history was 1.64 (95% CI 1.21--2.22, *P* = 0.16 for heterogeneity) (Fig. [3](#Fig3){ref-type="fig"}); for PD, the OR for women with family history was 1.35 (95% CI 1.09--1.69, *P* = 0.22 for heterogeneity) (Fig. [4](#Fig4){ref-type="fig"}); and for PDWA, the OR for women with family history was 1.61 (95% CI 1.17--2.22, *P* = 0.66 for heterogeneity).Fig. 3Forest plot for meta-analysis of breast cancer risk from non-proliferative disease for women with a first-degree family history compared to women without family history. The width of the *horizontal line* represents the 95% CI of the individual studies, and the *square* proportional represents the weight of each study. The *diamond* represents the pooled OR and 95% CIFig. 4Forest plot for meta-analysis of breast cancer risk from proliferative disease for women with a first-degree family history compared to women without family history. The width of the *horizontal line* represents the 95% CI of the individual studies, and the *square* proportional represents the weight of each study. The *diamond* represents the pooled OR and 95% CI

Funnel plot and Egger's test were performed to access the publication bias of literatures. In overall studies, no significant publication bias (*P* \> 0.05) existed (data not shown).

Discussion {#Sec9}
==========

The present meta-analysis was conducted to investigate the subtype of BBD with high breast cancer risk and the influence of a positive family history on various subtypes of BBD. This study showed that all subtypes of BBD increased the subsequent breast cancer risk, and ALH had a highest risk. Furthermore, our results suggested that a first-degree family history increased risk in women with NP and PD. Although compared to women without family history and PD, women with a first-degree family history and AH had the highest risk; a first-degree family history did not increase risk in women with AH. Increased screening, chemoprevention, and even prophylactic surgery should be considered for women with ALH or women with a first-degree family history and AH.

Consistent with previous studies, our study showed that PDWA had a slightly increased risk (OR = 1.44, 95% CI 1.28--1.63) of breast cancer, and AH had a substantially increased risk (OR = 2.81, 95% CI 1.91--4.12). Worsham et al. ([@CR34]) suggested that breast cancer risk from BBD for women with ADH may be higher than for women with ALH. However, the opposite results were reported in other studies (Fitzgibbons et al. [@CR12]; Kabat et al. [@CR17]; Collins et al. [@CR6]). This meta-analysis suggested that breast cancer risk from BBD for women with ALH (OR = 5.14, 95% CI 3.52--7.52) may be higher than for women with ADH (OR = 2.93, 95% CI 2.16-3.97). Previous study (Hartmann et al. [@CR15]) showed that degree of family history was an independent risk factor. The risk ratio of breast cancer for NP women with a weak family history was 1.12, but no significant difference was observed. The women with a first-degree family history were included in this study for investigating the interplay between BBD and family history of breast cancer, and the first-degree family history was a significant risk factor for women with different histological subtypes of BBD except for AH. The future large study should be carried out to evaluate the breast cancer risk for women with different degrees of family history.

Recommendations for breast cancer screening and risk-reduction options for women at average risk were different from women at high risk (Griffin and Pearlman [@CR14]). Routine mammography should be performed for women at average risk, but no special risk-reduction management should be done (Griffin and Pearlman [@CR14]; Meissner et al. [@CR27]). However, increased screening, chemoprevention, and prophylactic surgery should be considered for women at high risk. This meta-analysis suggested that women with AH, especially for ALH and AH combined with a first-degree family history, were at high risk, so that risk-reduction options should be considered.

Several issues may affect the efficiency of specific types of BBD with risk of breast cancer. First, the reference group used to examine the subsequent breast cancer risk among women with BBD was variant in different studies. The general population was used as reference group in some studies (Hartmann et al. [@CR15]; Carter et al. [@CR4]; McDivitt et al. [@CR26]; Degnim et al. [@CR7]), while NP was used in others (Dupont and Page [@CR9]; London et al. [@CR23]; Marshall et al. [@CR25]; Worsham et al. [@CR35]; Jacobs et al. [@CR16]). In this meta-analysis, NP was used as reference group for calculation although data were extracted from studies with different reference groups. Therefore, this study gave a more precise estimation of the risk from a large sample. Second, there was no pathological review in some studies (Wang et al. [@CR33]), and the classification of BBD was unequal in different centers (King et al. [@CR19]; Patterson et al. [@CR29]). However, the breast lesions included in this meta-analysis were all biopsy-proved BBD and reviewed by experienced pathologists.

On the other hand, some limitations still exist in this meta-analysis. First, both very old and relatively new studies were included in this study; the methodological limitation of this analysis should be considered. Second, of these ten studies, most subjects were Caucasians, including some African-Americans, while no Asians were included. Therefore, the conclusion in Asian populations was still unclear. Third, the present results were based on unadjusted ORs, and more precise estimation may be adjusted by other potential covariates.

In conclusion, this meta-analysis strongly suggested that women with AH, especially for ALH and AH combined with a first-degree family history, were at high risk. So risk-reduction options should be considered for these women. Further study with larger sample size is necessary to get more precise estimation of breast cancer risk after diagnosis of BBD.
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